Skip to main content

Ralstonia infection in cystic fibrosis

  • H. D. GREEN (a1) (a2), R. BRIGHT-THOMAS (a1) (a2), D. T. KENNA (a3), J. F. TURTON (a3), N. WOODFORD (a3) and A. M. JONES (a1) (a2)...

This study aimed to determine prevalence of Ralstonia spp. in cystic fibrosis patients, look for any evidence of cross infection and to describe clinical outcomes for patients infected by Ralstonia spp. Prevalence of Ralstonia spp. was calculated annually from 2008 to 2016. Pulsed-field gel electrophoresis was performed on ⩾1 sample from patients with an isolation of Ralstonia spp. between 2008 and 2016. A prospective, longitudinal observational study of adult patients was performed with 12 months follow-up from recruitment. Prevalence of Ralstonia spp. rose from 0·6% in 2008 to 2·4% in 2016. In total 12 out of 14 (86%) patients with ⩾1 isolation of Ralstonia spp. developed chronic infection. A pair and a group of three unrelated patients with epidemiological connections shared strains of Ralstonia mannitolilytica. Lung function of Ralstonia spp. infected patients was moderately to severely impaired. Prevalence of Ralstonia spp. is low but increasing. The risk of a patient developing chronic Ralstonia spp. infection following first acquisition is high and cross-infection may be possible. Whether Ralstonia spp. infection causes increased pulmonary exacerbation frequency and lung function decline needs to be evaluated in larger prospective studies.

Corresponding author
*Author for correspondence: Dr Heather Green, Manchester Adult Cystic Fibrosis Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK (E-mail:
Hide All
1.Cystic Fibrosis Foundation Patient registry 2010 annual data report.
2. Dalbøge, CS, et al. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. Journal Cystic Fibrosis 2011; 10: 318325.
3.Cystic Fibrosis Foundation Patient registry 2005 annual data report.
4.Cystic Fibrosis Foundation Patient registry 2011 annual data report.
5. Lipuma, JJ. The changing microbial epidemiology in cystic fibrosis. Clinical Microbiology Reviews 2010; 23: 299323.
6. Yabuuchi, E, et al. Transfer of Two Burkholderia and an Alcaligenes species to Ralstonia Gen. Nov: proposal of Ralstonia picketii (Ralston, Palleroni and Doudoroff 1973) Comb. Nov., Ralstonia solanacearum (Smith 1896) Comb. Nov and Ralstonia eutropha (Davis 1969) Comb. Nov. Microbiology and Immunology 1995; 39: 897904.
7. Coenye, T, et al. Classification of Ralstonia pickettii-like isolates from the environment and clinical samples as Ralstonia insidiosa sp. nov. International Journal of Systematic Evolutionary Microbiology 2003; 53: 10751080.
8. Safni, I, et al. Polyphasic taxonomic revision of the Ralstonia solanacearum species complex: proposal to emend the descriptions of Ralstonia solanacearum and Ralstonia syzygii and reclassify current R. syzygii strains as Ralstonia syzygii subsp. syzygii subsp. nov., R. s. Journal of Systematic Evolutionary Microbiolgy 2014; 64: 30873103.
9. Coenye, T, Vandamme, P, and Lipuma, JJ. Infection by Ralstonia species in cystic fibrosis patients: identification of R.pickettii and R.mannitolilytica by Polymerase Chain Reaction. Emerging Infectious Diseases Journal 2002; 8: 692696.
10. Coenye, T, et al. Use of PCR analyses to define the distribution of Ralstonia species recovered from patients with cystic fibrosis. Journal of Clinical Microbiology 2005; 43: 34633466.
11. Burns, JL, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clinical Infectious Diseases 1998; 27: 158163.
12. Coman, I, et al. Ralstonia mannitolilytica in cystic fibrosis: a new predictor of worse outcomes. Respiratory Medicine Case Reports 2017; 20: 4850.
13. Kenna, D, et al. Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients. Journal of Medical Microbiology 2017; 66: 490501.
14. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016.
15. The British Society for Antimicrobial Chemotherapy, Methods for Antimicrobial Susceptibility Testing. Version 14. 2015.
16. Kaufmann, ME. Pulsed-field gel electrophoresis. Methods in Molecular Microbiology 1998; 15: 3350.
17. Littlewood, J, et al. Pseudomonas aeruginosa infection in people with cystic fibrosis: suggestions for prevention and infection control, in Report of the UK Cystic Fibrosis Trust Infection Control Group, 2004.
18. Littlewood, J, et al. The Burkholderia cepacia Complex: suggestions for prevention and infection control, in Report of the UK Cystic Fibrosis Trust Infection Control Group, 2004.
19. Jones, A, et al. Methicillin-resistant Staphylococcus aureus (MRSA), in Report of the UK Cystic Fibrosis Trust Infection Control Working Group, 2008.
20.Laboratory standards for processing microbiological samples from people with cystic fibrosis. Report of the UK Cystic Fibrosis Trust Microbiology Laboratory Standards Working Group First Edition, 2010.
21. Miller, MR, et al. Standardisation of spirometry. European Respiratory Journal 2005; 26: 319338.
22. Lee, TWR, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis 2003; 2: 2934.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary materials

Green supplementary material
Figure S1

 Word (20 KB)
20 KB


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed